Inicio>>CT-2584

CT-2584 (Synonyms: 1-(11-Dodecylamino-10-hydroxyundecyl)-3,7-dimethylxanthine methane sulfonate)

Catalog No.GB40162

CT-2584 (166981-13-1; free base) is a cytotoxic agent that alters phospholipid biosynthesis via inhibition of CTP:choline-phosphate cytidylyltransferase causing an increase in phosphatidylinositol with decreasing levels of phosphatidylcholine. The altered phospholipid metabolism caused by CT-2584 results in a loss of lamellar structure and membrane integrity (especially in mitochondria and endoplasmic reticulum). CT-2584 was active against a wide range of tumor cell lines including multi-drug resistant lines.

Products are for research use only. Not for human use. We do not sell to patients.

CT-2584 Chemical Structure

Cas No.: 166981-13-1

Tamaño Precio Disponibilidad Cantidad
5mg
375,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

CT-2584 (166981-13-1; free base) is a cytotoxic agent that alters phospholipid biosynthesis via inhibition of CTP:choline-phosphate cytidylyltransferase causing an increase in phosphatidylinositol with decreasing levels of phosphatidylcholine. The altered phospholipid metabolism caused by CT-2584 results in a loss of lamellar structure and membrane integrity (especially in mitochondria and endoplasmic reticulum). CT-2584 was active against a wide range of tumor cell lines including multi-drug resistant lines.

Reseñas

Review for CT-2584

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for CT-2584

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.